Table 1.
Lenvatinib (n=62) | |
---|---|
Age (years), median (range) | 74 (49–93) |
Age group (years) | |
<65 | 10 (16%) |
≥65 to <75 | 22 (36%) |
≥75 | 30 (48%) |
Gender: male/female (%) | 53 (85%)/9 (15%) |
Bodyweight (kg) | |
<60 | 30 (48%) |
≥60 | 32 (52%) |
Etiology of chronic liver disease | |
HBV | 12 (19%) |
HCV | 30 (48%) |
Alcohol | 8 (13%) |
Others | 12 (19%) |
Child–Pugh class | |
A | 54 (87%) |
B | 8 (13%) |
ECOG PS | |
0 | 42 (68%) |
1 | 20 (32%) |
BCLC | |
B (intermediate stage) | 25 (40%) |
C (advanced stage) | 37 (60%) |
Extrahepatic spread | |
Yes | 26 (42%) |
No | 36 (58%) |
Macroscopic vascular invasion | |
Yes | 17 (27%) |
No | 45 (73%) |
Baseline AFP concentration | |
Median | 113.1 (1.6–70 000) |
Baseline AFP concentration group (ng/mL) | |
<200 | 34 (55%) |
≥200 | 27 (44%) |
Missing | 1 (1%) |
Concomitant systemic antiviral therapy for HBV or HCV | 19 (31%) |
Clinical course (systemic therapy) | |
First line | 39 (63%) |
Second line | 6 (10%) |
Third line | 17 (27%) |
Median LEN treatment duration (days) | 156.5 (30–662) |
AFP, alpha‐fetoprotein; BCLC, Barcelona Clinic Liver Cancer; HBV, hepatitis B virus; HCV, hepatitis C virus; LEN, lenvatinib; PS, performance status.